Axovant Sciences Ltd. (AXON) Receives “Buy” Rating from Jefferies Group
Other equities research analysts also recently issued research reports about the company. HC Wainwright reiterated a buy rating on shares of Axovant Sciences in a report on Wednesday, August 17th. Zacks Investment Research upgraded Axovant Sciences from a hold rating to a buy rating and set a $17.00 price target for the company in a report on Monday, August 8th. Evercore ISI reiterated a buy rating and set a $29.00 price target on shares of Axovant Sciences in a report on Friday, September 23rd. JMP Securities reissued a buy rating on shares of Axovant Sciences in a research report on Tuesday, November 8th. Finally, Robert W. Baird reissued an outperform rating and issued a $29.00 price objective on shares of Axovant Sciences in a research report on Friday, September 23rd. One analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus price target of $26.33.
Axovant Sciences (NYSE:AXON) traded down 0.07% on Thursday, reaching $13.75. The company’s stock had a trading volume of 28,674 shares. Axovant Sciences has a 12 month low of $8.86 and a 12 month high of $21.30. The firm’s market cap is $1.36 billion. The firm has a 50 day moving average of $13.13 and a 200 day moving average of $13.76.
Axovant Sciences (NYSE:AXON) last announced its quarterly earnings results on Monday, August 15th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.36) by $0.02. Analysts anticipate that Axovant Sciences will post ($1.72) earnings per share for the current year.
Hedge funds have recently modified their holdings of the company. Wells Fargo & Company MN raised its position in shares of Axovant Sciences by 1.5% in the third quarter. Wells Fargo & Company MN now owns 8,130 shares of the company’s stock worth $113,000 after buying an additional 117 shares in the last quarter. SG Americas Securities LLC acquired a new position in shares of Axovant Sciences during the third quarter worth $124,000. GSA Capital Partners LLP acquired a new position in shares of Axovant Sciences during the second quarter worth $128,000. Royal Bank of Canada raised its position in shares of Axovant Sciences by 467.6% in the second quarter. Royal Bank of Canada now owns 10,500 shares of the company’s stock worth $135,000 after buying an additional 8,650 shares in the last quarter. Finally, Princeton Capital Management Inc. acquired a new position in shares of Axovant Sciences during the third quarter worth $145,000. 28.89% of the stock is currently owned by institutional investors and hedge funds.
Axovant Sciences Company Profile
Axovant Sciences Ltd., formerly Roivant Neurosciences Ltd., is a clinical-stage biopharmaceutical company focused on acquiring, developing and commercializing therapeutics for the treatment of dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.
Receive News & Stock Ratings for Axovant Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd. and related stocks with our FREE daily email newsletter.